1. Cell Biology

Native adiponectin in serum binds to mammalian cells expressing T-cadherin, but not AdipoRs or calreticulin

  1. Shunbun Kita  Is a corresponding author
  2. Shiro Fukuda
  3. Norikazu Maeda
  4. Iichiro Shimomura
  1. Osaka University, Japan
https://doi.org/10.7554/eLife.48675
Share this article
Cite this article
  1. Shunbun Kita
  2. Shiro Fukuda
  3. Norikazu Maeda
  4. Iichiro Shimomura
(2019)
Native adiponectin in serum binds to mammalian cells expressing T-cadherin, but not AdipoRs or calreticulin
eLife 8:e48675.
https://doi.org/10.7554/eLife.48675
  2. Download BibTeX
  3. Download .RIS

Abstract

Adiponectin is an adipocyte-derived atypically abundant circulating factor that protects various organs and tissues through its receptors, AdipoRs, calreticulin, and T-cadherin. To identify the major binding partner of circulating native adiponectin, we expressed these receptors on the surface of HEK293 cells. Adiponectin, either that in mouse or human serum, purified from serum, or produced by mammalian cells, bound to cells expressing T-cadherin, but not to those expressing AdipoR1 or calreticulin. The stable introduction of T-cadherin and AdipoR1 into CHO cells resulted in the cell surface localization of these receptors. Native adiponectin in serum bound to cells expressing T-cadherin, not to those expressing AdipoR1. The knockdown of T-cadherin, but not AdipoRs resulted in the significant attenuation of native adiponectin binding to C2C12 myotubes. Therefore, native adiponectin binding depended on the amount of T-cadherin expressed in HEK293 cells, CHO cells, and C2C12 myotubes. Collectively, our mammalian cell-based studies suggest that T-cadherin is the major binding partner of native adiponectin in serum.

https://doi.org/10.7554/eLife.48675.001

Introduction

Adiponectin is a circulating factor that is secreted from adipocytes (Hu et al., 1996; Maeda et al., 1996; Nakano et al., 1996; Scherer et al., 1995). Three types of receptors have been identified for this uniquely abundant circulating protein: AdipoRs, calreticulin, and T-cadherin.

AdipoR1 was discovered by expression cloning from a C2C12 myotube cDNA library through evaluations of the binding of biotin-labeled globular adiponectin produced in E. coli as bait (Yamauchi et al., 2003). It belongs to the PAQR receptor family, which has a 7-transmembrane domain with an opposite topology to the GPCR family (Tang et al., 2005).

Calreticulin is an endoplasmic reticulum (ER) luminal Ca2+-buffering chaperone that exists in the ER of cells (Mendlov and Conconi, 2010; Michalak et al., 2009). Cell surface exposure to calreticulin was initially reported to initiate the clearance of viable or apoptotic cells through binding to LRP on phagocytes (Gardai et al., 2005). A subsequent study demonstrated that adiponectin opsonized apoptotic cells, and the phagocytosis of cell corpses was mediated by the binding of adiponectin expressed in insect cells or E. coli to calreticulin on the macrophage cell surface (Takemura et al., 2007).

T-Cadherin was discovered by expression cloning from a C2C12 myotube cDNA library through evaluations of cell binding to coated recombinant adiponectin produced in HEK293 mammalian cells (Hug et al., 2004). It is classified as a member of the classical cadherins, such as E-cadherin and N-cadherin, due to its high homology of five extracellular cadherin repeats (Hulpiau and van Roy, 2009). However, T-cadherin is a unique cadherin with a glycosylphosphatidylinositol (GPI) anchor on its C terminus and does not possess the transmembrane or intracellular domain generally required for signaling, which may hinder the function of T-cadherin as an adiponectin receptor.

The adiponectin protein accumulates in tissues, such as the heart, muscle, and vascular endothelium, through binding with T-cadherin (Denzel et al., 2010; Fujishima et al., 2017; Matsuda et al., 2015; Parker-Duffen et al., 2013; Tanaka et al., 2019). In T-cadherin null mice, the accumulation of the adiponectin protein was completely absent in these tissues, and, thus, HMW multimer adiponectin accumulated in blood (Denzel et al., 2010; Matsuda et al., 2015; Parker-Duffen et al., 2013). These findings were in contrast to the lack of significant changes in plasma adiponectin levels in AdipoR1- and R2-double knockout mice (Yamauchi et al., 2007). Human SNP studies including GWAS also indicated the importance of T-cadherin, but not AdipoRs or calreticulin, for plasma adiponectin levels, cardiovascular diseases, and glucose homeostasis (Buniello et al., 2019; Chung et al., 2011; Dastani et al., 2012; Kitamoto et al., 2016; Morisaki et al., 2012).

Numerous studies have attributed the functions of adiponectin to either of these receptors by showing a decrease in their functions via the genetic loss or mRNA knockdown of their receptors, including AdipoRs (Straub and Scherer, 2019; Yamauchi et al., 2014; Yamauchi et al., 2003; Yamauchi et al., 2007), calreticulin (Takemura et al., 2007), and T-cadherin (Denzel et al., 2010; Fujishima et al., 2017; Parker-Duffen et al., 2013; Tanaka et al., 2019). However, the direct binding of native adiponectin in biological fluids, such as serum, to its receptor warrants further study.

We herein demonstrated that native adiponectin in serum bound to cells expressing T-cadherin, but not to those expressing AdipoRs or calreticulin.

Results and discussion

We investigated the binding of native adiponectin in serum to three adiponectin receptors by transiently overexpressing the cDNA of each receptor in HEK293 cells (Figure 1A). We directly examined mouse serum as the ligand solution, including the most native adiponectin, purified adiponectin from mouse serum (Fukuda et al., 2017), and full-length recombinant adiponectin produced in HEK293 cells. Native-PAGE showed differences in the distribution of molecular species between serum or purified adiponectin and recombinant adiponectin (Figure 1B). Recombinant adiponectin contained a lower amount of HMW multimer adiponectin than mouse serum and purified adiponectin from serum (Figure 1B). Transient transfection resulted in the successful overexpression of each receptor based on their expression levels quantified by RT-qPCR (Figure 1C). The treatment of cells with different preparations of adiponectin at 4°C for 1 hr resulted in the binding of prepared adiponectin only to cells expressing mouse T-cadherin (Figure 1D). Mouse serum and purified adiponectin showed similar binding, whereas recombinant adiponectin containing a lower amount of 6-mer and the HMW multimer exhibited markedly weaker binding (Figure 1D). The results of a native-PAGE analysis showed that more than 6-mer of multimeric adiponectin specifically bound to cells expressing mouse T-cadherin (Figure 1—figure supplement 1), which is consistent with previous findings (Fukuda et al., 2017; Hug et al., 2004). The dose-response study revealed the specific and saturable binding of native adiponectin in serum to cells expressing T-cadherin (Figure 1E).

Figure 1 with 2 supplements see all
Download asset Open asset
Mouse serum adiponectin binds only to the hek293 cells expressing t-cadherin.

(A) Experimental outline. HEK293 cells were transfected with mammalian expression vectors coding mouse T-cadherin (mCdh13), Calreticulin (mCalr), or AdipoR1 (mAdipor1). (B) Native-page analysis of adiponectin preparations. Adiponectin concentrations were measured by ELISA and the equal amount (50 ng) of adiponectin was analyzed. (C) Absolute copy numbers of mRNA levels of mouse mCdh13, mCalr, mAdipor1, and mAdipor2 were quantified. (D) Binding of adiponectin to HEK293 cells expressing none (N), mock (M), T-cadherin (T), or AdipoR1 (R1) (E) Dose-response cell-based binding study. Mouse serum (20 μg adiponectin/mL) was diluted and applied to the cells expressing mock or T-cadherin (left). The bound adiponectin was evaluated by blot intensity (right). Cell lysate following binding was separated by SDS-page and native-page. Essentially same results were obtained from more than three independent experiments.

https://doi.org/10.7554/eLife.48675.002

Similar results were obtained when human cDNAs were overexpressed and the binding of adiponectin in human serum was assessed (Figure 1—figure supplement 2A–D). We previously reported that purified recombinant T-cadherin bound purified adiponectin with an affinity of KD = 1.0 nM (Fukuda et al., 2017). The present results showed the saturable binding of native adiponectin in serum to cells expressing T-cadherin, which is consistent with previous findings (Fukuda et al., 2017). Regarding AdipoR1 and calreticulin, three possibilities have been proposed: they were not effectively translated, were not effectively presented on the cell surface, or did not support the binding of native adiponectin in serum to cells.

To confirm that all receptors were effectively translated and presented on the cell surface, we expressed affinity-tagged receptors in HEK293 cells (Figure 2A). We added a high-affinity PA tag (Fujii et al., 2014) to the N termini of T-cadherin (Ciatto et al., 2010) and calreticulin (Mendlov and Conconi, 2010) and to the C terminus of AdipoR1 (Yamauchi et al., 2014) such that each receptor exposed the PA tag outside of the cell. Transiently expressing cells were surface-biotinylated, and lysates were applied to streptavidin beads. Total cell lysates (Figure 2B Total) and streptavidin-captured cell-surface proteins (Figure 2B Cell surface) were analyzed by Western blotting. The anti-PA-tag antibody NZ-1 detected similar levels of all receptors in total cell lysates and cell surface fractions, indicating that these receptors were successfully translated and expressed on the cell surface. Although AdipoR1 poorly migrated on the SDS-PAGE gel, this may have been due to heat-induced protein crosslinking or aggregate formation during sample processing (Tanford and Reynolds, 1976). The correct sorting of this protein to the cell surface suggested that AdipoR1 was expressed with the correct conformation on the cell surface. Under these conditions, a binding study with mouse serum revealed the dose-dependent binding of native adiponectin to cells expressing PA-tagged T-cadherin, but not to those expressing PA-tagged calreticulin or AdipoR1 (Figure 2C). Taken together with the results of the overexpression study (Figure 1), native adiponectin in serum bound to cells expressing T-cadherin, but not those expressing calreticulin or AdipoR1.

Figure 2
Download asset Open asset
Cell surface expression of adiponectin receptors.

(A) Experimental outline of transient expression in HEK293 cells. (B) Surface protein biotinylation analysis. Cell surface biotinylated proteins trapped on Streptavidin beads were eluted and analyzed in SDS-page in two lanes; x1 and x5 concentrations. Note that PA-tag antibody NZ-1 react with human podoplanin (40 KDa) in addition to PA-tagged proteins. GAPDH; control cytosolic protein. (C) Binding of mouse adiponectin in mouse serum (MS) to HEK293 cells. (D) Experimental outline of stable CHO cells expressing adiponectin receptors. (E) stable expressions detected by NZ-1. (F) Binding of mouse adiponectin in mouse serum to CHO cells. Adiponectin-binding from western blots (left) was calculated and expressed in right graph. Data are mean ± SEM. n = 4 ***p<0.01 (unpaired t-test). (G) Binding of NZ-1 antibody to CHO cells. NZ-1-binding from western blots (left) was calculated and expressed in right graph. Data are mean ± SEM. n = 4 ***p<0.001 (unpaired t-test). (H) Confocal immunofluorescence micrographs of CHO cells stained with anti-PA tag antibody NZ-1 (green). Cell nuclei were counterstained with DAPI (blue). Scale bars = 250 nm.

https://doi.org/10.7554/eLife.48675.005

We then generated stably expressing CHO cells (Figure 2D). The successful expression of the receptors in these cells was confirmed by Western blotting (Figure 2E). Serum adiponectin binding was only observed on cells expressing PA-tagged T-cadherin (Figure 2F). In contrast, the binding of the PA tag antibody NZ-1 to intact cells was detected on cells expressing PA-tagged T-cadherin and AdipoR1 (Figure 2G). These results demonstrated that AdipoR1 was stably expressed on the cell surface with the expected topology of the PA tag outside of cells, but did not induce the binding of native adiponectin in serum. Calreticulin was not recognized by NZ-1 in the binding study (Figure 2G), suggesting that the PA tag at the N terminus of calreticulin was not accessible by NZ-1.

This may have been due to some steric hindrance because calreticulin with the N-terminal PA tag was detected on Western blots (Figure 2E) and immunostaining of fixed and permeabilized cells by NZ-1 (Figure 2H). Calreticulin is essentially an ER-resident protein (Gardai et al., 2005; Takemura et al., 2007). Therefore, stably expressed calreticulin in CHO cells may not have been sorted to the cell surface.

Based on these different approaches, we concluded that the expression of AdipoR1 may not promote native adiponectin binding. We also concluded that if calreticulin is expressed on the cell surface, it may not promote native adiponectin binding. The present results demonstrated that only the expression of T-cadherin on the cell surface may increase the binding of native adiponectin.

Since the above studies employed artificial expression systems, and AdipoR1 and T-cadherin were both identified from the C2C12 cDNA library (Hug et al., 2004; Yamauchi et al., 2003), we examined native adiponectin binding to C2C12 myotubes (Figure 3A). The absolute expression level of T-cadherin mRNA in differentiated C2C12 myotubes was markedly higher than that of AdipoRs (Figure 3B). We investigated the knockdown effects of these receptors on the binding of serum-containing adiponectin in C2C12 myotubes (Figure 3C,D). The introduction of RNAi before differentiation resulted in the effective knockdown of T-cadherin, AdipoR1, or AdipoR1 and R2 after 3 days of differentiation (Figure 3C). The knockdown of T-cadherin resulted in significant reductions in adiponectin binding (Figure 3D,E). The knockdown of AdipoR1 or both AdipoR1 and R2 did not significantly reduce adiponectin binding (Figure 3D,E). Although slight decreases were observed in adiponectin binding by the knockdown of AdipoR1 or both AdipoR1 and R2, the strong correlation (R2 = 0.9896) between T-cadherin expression and adiponectin binding at all experimental points suggested that these changes were due to the decreased expression of T-cadherin (Figure 3F,G). Collectively, these results indicated that native adiponectin binding also depends on the amount of T-cadherin expressed in C2C12 myotubes.

Figure 3
Download asset Open asset
Knockdown of T-cadherin but not Adipors nor calreticulin affected native adiponectin binding to c2c12 myotubes.

(A) Experimental outline. (B) Absolute expression levels of T-cadherin (mCdh13), AdipoR1 (mAdipor1), and AdipoR2 (mAdipor2) in differentiated C2C12 myotubes. (C) Knockdown efficiencies of adiponectin receptors. Data are mean ± SEM. n = 3 ***p<0.001 (unpaired t-test). (D) Binding of native adiponectin in mouse serum to C2C12 cells. Bound adiponectin was shown in representative western blot with a-tubulin as internal control and T-cadherin. (E) Adiponectin-binding. Data are mean ± SEM. n = 4 ***p<0.001 (unpaired t-test). (F) Amount of T-cadherin protein expression. Data are mean ± SEM. n = 4 ***p<0.001 (unpaired t-test). (G) Correlation between bound adiponectin and T-cadherin protein expression. n = 16 a linear regression r2 = 0.9896.

https://doi.org/10.7554/eLife.48675.006

Here, we simultaneously compared three adiponectin receptors. The expression of T-cadherin gave adiponectin binding, which is consistent with our previous finding showing that recombinant T-cadherin binds HMW adiponectin in a 1: one ratio with high affinity (Fukuda et al., 2017). There was no detectable binding of adiponectin on the AdipoR or calreticulin. AdipoR was discovered by expression cloning. The overexpression of AdipoR was expected to promote ligand binding. The initial discovery of AdipoRs also indicated that HEK293 cells overexpressing AdipoRs bound E. coli recombinant globular adiponectin (Yamauchi et al., 2003). Therefore, difficulties are associated with speculating about the much weaker affinity or the requirement for some ‘accessory’ proteins to confer adiponectin binding activity to AdipoRs.

Since numerous studies indicated that AdipoRs mediate adiponectin signaling in a number of cell types, an additional activating mechanism for AdipoRs by adiponectin, that is, the reductive or proteolytic generation of the trimer, monomer, and/or globular adiponectin, may exist. The results of the present study, which focused on the direct binding of native HMW adiponectin, may indicate the activation of AdipoRs by low-molecular-weight (LMW) forms. On the other hand, in the case of calreticulin, this was evidenced by a neutralizing antibody treatment inhibiting the adiponectin interaction with cells (Takemura et al., 2007). Therefore, some ‘accessory’ proteins may be required to confer adiponectin binding activity to calreticulin.

T-cadherin binds clinically important HMW multimer adiponectin with high affinity (Fukuda et al., 2017) and mediates adiponectin-induced exosome biogenesis and ceramide efflux to exosomes (Obata et al., 2018). Such exosome-effect required T-cadherin, but not AdipoRs. The exosome mediates cell-cell communication by transferring signaling components such as microRNAs, bioactive lipids, and proteins in addition to its role in waste disposal (Kita et al., 2019; van Niel et al., 2018). The stimulation of exosome biogenesis by adiponectin was the first demonstration of a secreted factor modulating exosome biogenesis and secretion (Obata et al., 2018). Adiponectin in serum or purified native adiponectin together with T-cadherin accumulated inside multivesicular bodies, the site of exosome generation, both in cultured endothelial cells and the in vivo wild-type mouse aorta (Obata et al., 2018). The systemic level of exosomes in blood was decreased by approximately 50% following the genetic loss of adiponectin or T-cadherin, but was increased by the overexpression of adiponectin in mice (Obata et al., 2018). The molecular mechanisms by which adiponectin stimulates exosome biogenesis are currently under investigation. We speculate that native HMW adiponectin with its multimeric structure may cause the higher-order clustering of T-cadherin, a membrane-anchored protein that resides in lipid rafts, and, thus, may stimulate exosome biogenesis. Adiponectin-induced increases in exosome biogenesis were not restricted to cultured endothelial cells because they were also observed in C2C12-differentiated myotubes (Tanaka et al., 2019) These findings support T-cadherin mediating adiponectin functions as a receptor for native HMW multimer adiponectin (Kita et al., 2019). The present results may further contribute to clarifying the activating mechanism of AdipoRs by LMW adiponectin, generated by reduction or proteolytic cleavage, followed by HMW adiponectin binding to cell surface T-cadherin.

Materials and methods

Key resources table
Reagent type
(species) or
resource		DesignationSource or referenceIdentifiersAdditional
information
Antibodyanti-mouse adiponectinR and DAF1119goat polyclonal
WB (1:5000)
Antibodyanti-human adiponectinR and DAF1065goat polyclonal
WB (1:5000)
Antibodyanti-T-cadherinR and DAF3264goat polyclonal
WB (1:5000)
Antibodyanti-α-tubulinCell Signaling11H10rabbit polyclonal
WB (1:1000)
Antibodyanti-PA-tag (NZ-1)FUJIFILM012–25863rat monoclonal
WB (1:1000)
Commercial assay, kitCell Surface Biotinylation KitThermo Fisher (Pierce)89881
Biological sample (Mus musculus)SerumCLEA JapanC57BL6J jclFreshly isolated from C57BL6J mice, male
Biological sample (Homo sapiens)SerumFreshly isolated from healthy volunteers, male
Peptide, recombinant proteinFull-length mammalian recombinant mouse adiponectinBioVendorRD272023100
Peptide, recombinant proteinhigh-molecular weight purified mouse adiponectinFukuda et al., 2017
Sequence-based reagentmRplp0_FwGene DesignGGCCAATAAGGTGCCAGCT
Sequence-based reagentmRplp0_RvGene DesignTGATCAGCCCGAAGGAGAAG
Sequence-based reagentAdipor1_FwGene DesignAATGGGGCTCCTTCTGGTAAC
Sequence-based reagentAdipor1_RvGene DesignGGATGACTCTCCAACGTCCCT
Sequence-based reagentAdipor2_FwGene DesignGGAGTGTTCGTGGGCTTAGG
Sequence-based reagentAdipor2_RvGene DesignGCAGCTCCGGTGATATAGAGG
Sequence-based reagentmCdh13_FwGene DesignGCCCTCGTGAGCCTTCTTC
Sequence-based reagentmCdh13_RvGene DesignCACCCTGAGGTCCGTGATGT
Sequence-based reagentmCalr_FwGene DesignAAGATGCCCGATTTTACGCAC
Sequence-based reagentmCalr_RvGene DesignCCCACAGTCGATATTCTGCTC
Sequence-based reagenthRPLP0_FwGene DesignGGCGACCTGGAAGTCCAACT
Sequence-based reagenthRPLP0_RvGene DesignCCATCAGCACCACAGCCTTC
Sequence-based reagenthCDH13_FGene DesignAGTGTTCCATATCAATCAGCCAG
Sequence-based reagenthCDH13_RGene DesignCGAGACCTCATAGCGTAGCTT
Sequence-based reagenthADIPOR1_FGene DesignTCCTGCCAGTAACAGGGAAG
Sequence-based reagenthADIPOR1_RGene DesignGGTTGGCGATTACCCGTTTG
Sequence-based reagenthADIPOR2_FGene DesignCTGGATGGTACACGAAGAGGT
Sequence-based reagenthADIPOR2_RGene DesignTGGGCTTGTAAGAGAGGGGAC
Sequence-based reagenthCALR_FwGene DesignCTCTGTCGGCCAGTTTCGAG
Sequence-based reagenthCALR_RvGene DesignTGTATTCTGAGTCTCCGTGCAT
Cell line
(Homo sapiens)		HEK293 cellsATCCCRL-1573
RRID:CVCL_0045		DMEM+10%FBS
Cell line
(Cricetulus griseus)		CHO cellsATCCCCL-61
RRID:CVCL_0214		Ham's F12+10%FBS
Cell line
(Homo sapiens)		Plat-E cellsCosmobioRV-101
RRID:CVCL_B488		Ecotropic retrovirus packaging
DMEM+10%FBS
Cell line
(Mus musculus)		C2C12 cellsRIKEN cell bankRCB0987
RRID:CVCL_0188		C2C12 sleletal myoblast
DMEM+10%FBS
Recomninant DNA reagentmCdh13This paperMaterials and methods: plasmids
Recomninant DNA reagentmCalrThis paperMaterials and methods: plasmids
Recomninant DNA reagentmAdipor1This paperMaterials and methods: plasmids
Recomninant DNA reagenthCDH13This paperMaterials and methods: plasmids
Recomninant DNA reagenthCALRThis paperMaterials and methods: plasmids
Recomninant DNA reagenthADIPOR1This paperMaterials and methods: plasmids
Recomninant DNA reagentmCat1This paperMaterials and methods: plasmids

Plasmids

General PCR techniques were used for the construction of plasmids. All primers were purchased from GeneDesign, Inc. The full-length cDNAs of human and mouse T-cadherin (mCdh13), AdipoR1 (mAdipor1), and calreticulin (mCalr) were cloned into pcDNA mammalian expression plasmid vectors. The PA tag sequence (GVAMPGAEDDVV) was attached to the N termini of mouse T-cadherin and calreticulin and the C terminus of AdipoR1. Mouse mCat1 cDNA was cloned into a pcDNA mammalian expression plasmid vector.

Cell lines

Request a detailed protocol

Mammalian cell lines were obtained from the American Type Culture Collection or RIKEN BRC CELL BANK. All cell lines negative for mycoplasma contamination were maintained under conditions indicated in Key resources table.

Stably expressing CHO cells

Request a detailed protocol

PA-tagged receptor cDNAs were subcloned into the retrovirus packaging vector pMXs-neo, and the resultant vectors were used to transfect Plat-E cells, thereby generating recombinant retroviruses. CHO cells were transfected with a mouse mCat plasmid, and after 48 hr, the resultant cells were infected with recombinant retroviruses. G418 at 800 μg/mL was used to select stably introduced cells.

Antibodies

The following primary antibodies were used: goat polyclonal anti-mouse adiponectin (AF1119, R and D), goat polyclonal anti-human adiponectin (AF1065, R and D), goat polyclonal anti-T-cadherin (AF3264, R and D), rabbit monoclonal anti-α-tubulin (11H10, Cell Signaling), rat monoclonal anti-PA-tag (human podoplanin PLAG sequence) (012–25863, FUJIFILM), and rabbit monoclonal anti-GPADH (14C10, Cell Signaling Technology).

Animal

Request a detailed protocol

Mouse serum was obtained from male and female C57BL6J jcl mice. Mice were maintained at 22°C under a 12:12 hr light-dark cycle (lights on from 8:00 AM to 8:00 PM). The experimental protocol was approved as No. 28-072-023 by the Ethics Review Committee for Animal Experimentation of Osaka University School of Medicine. This study also conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health.

Binding study

Request a detailed protocol

Adiponectin binding studies were performed using serum as the source of adiponectin in situ without any processing. Cells were treated with the indicated concentrations of serum in serum-free DMEM at 4°C for 1 hr and then washed with serum-free DMEM three times. NZ-1 binding was performed by incubating cells with 1.0 μg/mL NZ-1 in DMEM containing 0.2%BSA at 4°C for 1 hr and washed with serum-free DMEM three times. Cell lysates were combined with Laemmli sample buffer for SDS-PAGE and heated at 98°C for 5 min or combined with native-page buffer (Suzuki et al., 2007).

Adiponectin concentration

Request a detailed protocol

Adiponectin concentrations in sample preparations were measured by ELISA (Otsuka Pharmaceutical Co.).

Western blotting

Request a detailed protocol

Whole cell lysates were loaded onto 4–20% gradient SDS-PAGE gels (Bio-Rad) and transferred to nitrocellulose membranes. Membranes were blocked with PVDF Blocking Reagent for the Can Get signal (TOYOBO), incubated with primary antibodies using Can Get signal solution 1 (TOYOBO) at 4°C overnight, and then incubated with secondary antibodies conjugated with HRP using Can Get signal solution 2 (TOYOBO) at room temperature (RT) for 60 min. Chemiluminescence signals developed with Chemi-Lumi One Super (Nacalai Tesque) were visualized by ChemiDoc Touch and quantitated using Image Lab software (Bio-Rad). A native-PAGE analysis of the multimer composition of adiponectin was performed according to the method described (Suzuki et al., 2007).

Cell surface protein biotinylation

Request a detailed protocol

Cell surface protein biotinylation and subsequent isolation were performed using the Cell Surface Biotinylation Kit (Pierce) according to the instructions provided by the manufacturer.

Immunofluorescence staining

Request a detailed protocol

Cells on coverslips were fixed with periodate-lysine-paraformaldehyde (PLP) for 30 min and incubated with 3% w/v BSA and 0.3% w/v Triton X-100 in Dulbecco’s phosphate-buffered saline without calcium or magnesium (PBS) for 60 min. Cells were then incubated with 10 μg/mL NZ-1 at 4°C overnight and then incubated with an Alexa-Fluor 488 secondary antibody at RT for 60 min. Cell nuclei were counterstained with DAPI. A microscopy analysis was performed using an Olympus FV1000D confocal laser scanning microscope system (Olympus).

Statistical analysis

Request a detailed protocol

Values were expressed as the mean ± SEM. Differences between variables were compared using the Student’s t-test. The probability (P) values of <0.05 were considered to be significant.

Data and software availability

Request a detailed protocol

All data were deposited in Dryad at https://doi.org/10.5061/dryad.82557c0.

Data availability

All data were deposited in Dryad at https://doi.org/10.5061/dryad.82557c0.

The following data sets were generated
    1. Kita S
    2. Fukuda S
    3. Maeda N
    4. Shimomura I
    (2019) Dryad Digital Repository
    Data from: Native adiponectin in serum binds to cells expressing T-cadherin, but not AdipoRs or calreticulin.
    https://doi.org/10.5061/dryad.82557c0

References

    1. Dastani Z
    2. Hivert MF
    3. Timpson N
    4. Perry JR
    5. Yuan X
    6. Scott RA
    7. Henneman P
    8. Heid IM
    9. Kizer JR
    10. Lyytikäinen LP
    11. Fuchsberger C
    12. Tanaka T
    13. Morris AP
    14. Small K
    15. Isaacs A
    16. Beekman M
    17. Coassin S
    18. Lohman K
    19. Qi L
    20. Kanoni S
    21. Pankow JS
    22. Uh HW
    23. Wu Y
    24. Bidulescu A
    25. Rasmussen-Torvik LJ
    26. Greenwood CM
    27. Ladouceur M
    28. Grimsby J
    29. Manning AK
    30. Liu CT
    31. Kooner J
    32. Mooser VE
    33. Vollenweider P
    34. Kapur KA
    35. Chambers J
    36. Wareham NJ
    37. Langenberg C
    38. Frants R
    39. Willems-Vandijk K
    40. Oostra BA
    41. Willems SM
    42. Lamina C
    43. Winkler TW
    44. Psaty BM
    45. Tracy RP
    46. Brody J
    47. Chen I
    48. Viikari J
    49. Kähönen M
    50. Pramstaller PP
    51. Evans DM
    52. St Pourcain B
    53. Sattar N
    54. Wood AR
    55. Bandinelli S
    56. Carlson OD
    57. Egan JM
    58. Böhringer S
    59. van Heemst D
    60. Kedenko L
    61. Kristiansson K
    62. Nuotio ML
    63. Loo BM
    64. Harris T
    65. Garcia M
    66. Kanaya A
    67. Haun M
    68. Klopp N
    69. Wichmann HE
    70. Deloukas P
    71. Katsareli E
    72. Couper DJ
    73. Duncan BB
    74. Kloppenburg M
    75. Adair LS
    76. Borja JB
    77. Wilson JG
    78. Musani S
    79. Guo X
    80. Johnson T
    81. Semple R
    82. Teslovich TM
    83. Allison MA
    84. Redline S
    85. Buxbaum SG
    86. Mohlke KL
    87. Meulenbelt I
    88. Ballantyne CM
    89. Dedoussis GV
    90. Hu FB
    91. Liu Y
    92. Paulweber B
    93. Spector TD
    94. Slagboom PE
    95. Ferrucci L
    96. Jula A
    97. Perola M
    98. Raitakari O
    99. Florez JC
    100. Salomaa V
    101. Eriksson JG
    102. Frayling TM
    103. Hicks AA
    104. Lehtimäki T
    105. Smith GD
    106. Siscovick DS
    107. Kronenberg F
    108. van Duijn C
    109. Loos RJ
    110. Waterworth DM
    111. Meigs JB
    112. Dupuis J
    113. Richards JB
    114. Voight BF
    115. Scott LJ
    116. Steinthorsdottir V
    117. Dina C
    118. Welch RP
    119. Zeggini E
    120. Huth C
    121. Aulchenko YS
    122. Thorleifsson G
    123. McCulloch LJ
    124. Ferreira T
    125. Grallert H
    126. Amin N
    127. Wu G
    128. Willer CJ
    129. Raychaudhuri S
    130. McCarroll SA
    131. Hofmann OM
    132. Segrè AV
    133. van Hoek M
    134. Navarro P
    135. Ardlie K
    136. Balkau B
    137. Benediktsson R
    138. Bennett AJ
    139. Blagieva R
    140. Boerwinkle E
    141. Bonnycastle LL
    142. Boström KB
    143. Bravenboer B
    144. Bumpstead S
    145. Burtt NP
    146. Charpentier G
    147. Chines PS
    148. Cornelis M
    149. Crawford G
    150. Doney AS
    151. Elliott KS
    152. Elliott AL
    153. Erdos MR
    154. Fox CS
    155. Franklin CS
    156. Ganser M
    157. Gieger C
    158. Grarup N
    159. Green T
    160. Griffin S
    161. Groves CJ
    162. Guiducci C
    163. Hadjadj S
    164. Hassanali N
    165. Herder C
    166. Isomaa B
    167. Jackson AU
    168. Johnson PR
    169. Jørgensen T
    170. Kao WH
    171. Kong A
    172. Kraft P
    173. Kuusisto J
    174. Lauritzen T
    175. Li M
    176. Lieverse A
    177. Lindgren CM
    178. Lyssenko V
    179. Marre M
    180. Meitinger T
    181. Midthjell K
    182. Morken MA
    183. Narisu N
    184. Nilsson P
    185. Owen KR
    186. Payne F
    187. Petersen AK
    188. Platou C
    189. Proença C
    190. Prokopenko I
    191. Rathmann W
    192. Rayner NW
    193. Robertson NR
    194. Rocheleau G
    195. Roden M
    196. Sampson MJ
    197. Saxena R
    198. Shields BM
    199. Shrader P
    200. Sigurdsson G
    201. Sparsø T
    202. Strassburger K
    203. Stringham HM
    204. Sun Q
    205. Swift AJ
    206. Thorand B
    207. Tichet J
    208. Tuomi T
    209. van Dam RM
    210. van Haeften TW
    211. van Herpt T
    212. van Vliet-Ostaptchouk JV
    213. Walters GB
    214. Weedon MN
    215. Wijmenga C
    216. Witteman J
    217. Bergman RN
    218. Cauchi S
    219. Collins FS
    220. Gloyn AL
    221. Gyllensten U
    222. Hansen T
    223. Hide WA
    224. Hitman GA
    225. Hofman A
    226. Hunter DJ
    227. Hveem K
    228. Laakso M
    229. Morris AD
    230. Palmer CN
    231. Rudan I
    232. Sijbrands E
    233. Stein LD
    234. Tuomilehto J
    235. Uitterlinden A
    236. Walker M
    237. Watanabe RM
    238. Abecasis GR
    239. Boehm BO
    240. Campbell H
    241. Daly MJ
    242. Hattersley AT
    243. Pedersen O
    244. Barroso I
    245. Groop L
    246. Sladek R
    247. Thorsteinsdottir U
    248. Wilson JF
    249. Illig T
    250. Froguel P
    251. van Duijn CM
    252. Stefansson K
    253. Altshuler D
    254. Boehnke M
    255. McCarthy MI
    256. Soranzo N
    257. Wheeler E
    258. Glazer NL
    259. Bouatia-Naji N
    260. Mägi R
    261. Randall J
    262. Elliott P
    263. Rybin D
    264. Dehghan A
    265. Hottenga JJ
    266. Song K
    267. Goel A
    268. Lajunen T
    269. Doney A
    270. Cavalcanti-Proença C
    271. Kumari M
    272. Timpson NJ
    273. Zabena C
    274. Ingelsson E
    275. An P
    276. O'Connell J
    277. Luan J
    278. Elliott A
    279. McCarroll SA
    280. Roccasecca RM
    281. Pattou F
    282. Sethupathy P
    283. Ariyurek Y
    284. Barter P
    285. Beilby JP
    286. Ben-Shlomo Y
    287. Bergmann S
    288. Bochud M
    289. Bonnefond A
    290. Borch-Johnsen K
    291. Böttcher Y
    292. Brunner E
    293. Bumpstead SJ
    294. Chen YD
    295. Chines P
    296. Clarke R
    297. Coin LJ
    298. Cooper MN
    299. Crisponi L
    300. Day IN
    301. de Geus EJ
    302. Delplanque J
    303. Fedson AC
    304. Fischer-Rosinsky A
    305. Forouhi NG
    306. Franzosi MG
    307. Galan P
    308. Goodarzi MO
    309. Graessler J
    310. Grundy S
    311. Gwilliam R
    312. Hallmans G
    313. Hammond N
    314. Han X
    315. Hartikainen AL
    316. Hayward C
    317. Heath SC
    318. Hercberg S
    319. Hillman DR
    320. Hingorani AD
    321. Hui J
    322. Hung J
    323. Kaakinen M
    324. Kaprio J
    325. Kesaniemi YA
    326. Kivimaki M
    327. Knight B
    328. Koskinen S
    329. Kovacs P
    330. Kyvik KO
    331. Lathrop GM
    332. Lawlor DA
    333. Le Bacquer O
    334. Lecoeur C
    335. Li Y
    336. Mahley R
    337. Mangino M
    338. Martínez-Larrad MT
    339. McAteer JB
    340. McPherson R
    341. Meisinger C
    342. Melzer D
    343. Meyre D
    344. Mitchell BD
    345. Mukherjee S
    346. Naitza S
    347. Neville MJ
    348. Orrù M
    349. Pakyz R
    350. Paolisso G
    351. Pattaro C
    352. Pearson D
    353. Peden JF
    354. Pedersen NL
    355. Pfeiffer AF
    356. Pichler I
    357. Polasek O
    358. Posthuma D
    359. Potter SC
    360. Pouta A
    361. Province MA
    362. Rayner NW
    363. Rice K
    364. Ripatti S
    365. Rivadeneira F
    366. Rolandsson O
    367. Sandbaek A
    368. Sandhu M
    369. Sanna S
    370. Sayer AA
    371. Scheet P
    372. Seedorf U
    373. Sharp SJ
    374. Shields B
    375. Sigurðsson G
    376. Sijbrands EJ
    377. Silveira A
    378. Simpson L
    379. Singleton A
    380. Smith NL
    381. Sovio U
    382. Swift A
    383. Syddall H
    384. Syvänen AC
    385. Tönjes A
    386. Uitterlinden AG
    387. van Dijk KW
    388. Varma D
    389. Visvikis-Siest S
    390. Vitart V
    391. Vogelzangs N
    392. Waeber G
    393. Wagner PJ
    394. Walley A
    395. Ward KL
    396. Watkins H
    397. Wild SH
    398. Willemsen G
    399. Witteman JC
    400. Yarnell JW
    401. Zelenika D
    402. Zethelius B
    403. Zhai G
    404. Zhao JH
    405. Zillikens MC
    406. Borecki IB
    407. Meneton P
    408. Magnusson PK
    409. Nathan DM
    410. Williams GH
    411. Silander K
    412. Bornstein SR
    413. Schwarz P
    414. Spranger J
    415. Karpe F
    416. Shuldiner AR
    417. Cooper C
    418. Serrano-Ríos M
    419. Lind L
    420. Palmer LJ
    421. Hu FB
    422. Franks PW
    423. Ebrahim S
    424. Marmot M
    425. Kao WH
    426. Pramstaller PP
    427. Wright AF
    428. Stumvoll M
    429. Hamsten A
    430. Buchanan TA
    431. Valle TT
    432. Rotter JI
    433. Penninx BW
    434. Boomsma DI
    435. Cao A
    436. Scuteri A
    437. Schlessinger D
    438. Uda M
    439. Ruokonen A
    440. Jarvelin MR
    441. Peltonen L
    442. Mooser V
    443. Sladek R
    444. Musunuru K
    445. Smith AV
    446. Edmondson AC
    447. Stylianou IM
    448. Koseki M
    449. Pirruccello JP
    450. Chasman DI
    451. Johansen CT
    452. Fouchier SW
    453. Peloso GM
    454. Barbalic M
    455. Ricketts SL
    456. Bis JC
    457. Feitosa MF
    458. Orho-Melander M
    459. Melander O
    460. Li X
    461. Li M
    462. Cho YS
    463. Go MJ
    464. Kim YJ
    465. Lee JY
    466. Park T
    467. Kim K
    468. Sim X
    469. Ong RT
    470. Croteau-Chonka DC
    471. Lange LA
    472. Smith JD
    473. Ziegler A
    474. Zhang W
    475. Zee RY
    476. Whitfield JB
    477. Thompson JR
    478. Surakka I
    479. Spector TD
    480. Smit JH
    481. Sinisalo J
    482. Scott J
    483. Saharinen J
    484. Sabatti C
    485. Rose LM
    486. Roberts R
    487. Rieder M
    488. Parker AN
    489. Pare G
    490. O'Donnell CJ
    491. Nieminen MS
    492. Nickerson DA
    493. Montgomery GW
    494. McArdle W
    495. Masson D
    496. Martin NG
    497. Marroni F
    498. Lucas G
    499. Luben R
    500. Lokki ML
    501. Lettre G
    502. Launer LJ
    503. Lakatta EG
    504. Laaksonen R
    505. Kyvik KO
    506. König IR
    507. Khaw KT
    508. Kaplan LM
    509. Johansson Å
    510. Janssens AC
    511. Igl W
    512. Hovingh GK
    513. Hengstenberg C
    514. Havulinna AS
    515. Hastie ND
    516. Harris TB
    517. Haritunians T
    518. Hall AS
    519. Groop LC
    520. Gonzalez E
    521. Freimer NB
    522. Erdmann J
    523. Ejebe KG
    524. Döring A
    525. Dominiczak AF
    526. Demissie S
    527. Deloukas P
    528. de Faire U
    529. Crawford G
    530. Chen YD
    531. Caulfield MJ
    532. Boekholdt SM
    533. Assimes TL
    534. Quertermous T
    535. Seielstad M
    536. Wong TY
    537. Tai ES
    538. Feranil AB
    539. Kuzawa CW
    540. Taylor HA
    541. Gabriel SB
    542. Holm H
    543. Gudnason V
    544. Krauss RM
    545. Ordovas JM
    546. Munroe PB
    547. Kooner JS
    548. Tall AR
    549. Hegele RA
    550. Kastelein JJ
    551. Schadt EE
    552. Strachan DP
    553. Reilly MP
    554. Samani NJ
    555. Schunkert H
    556. Cupples LA
    557. Sandhu MS
    558. Ridker PM
    559. Rader DJ
    560. Kathiresan S
    561. DIAGRAM+ Consortium
    562. MAGIC Consortium
    563. GLGC Investigators
    564. MuTHER Consortium
    565. DIAGRAM Consortium
    566. GIANT Consortium
    567. Global B Pgen Consortium
    568. Procardis Consortium
    569. MAGIC investigators
    570. GLGC Consortium
    (2012) Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals
    PLOS Genetics 8:e1002607.
    https://doi.org/10.1371/journal.pgen.1002607
    1. Mendlov F
    2. Conconi M
    (2010)
    Calreticulin: a multifaceted protein
    Nature Education 4:1.

Article and author information

Author details

  1. Shunbun Kita

    1. Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan
    2. Department of Adipose Management, Graduate School of Medicine, Osaka University, Osaka, Japan
    Contribution
    Conceptualization, Resources, Software, Formal analysis, Funding acquisition, Investigation, Visualization, Methodology, Writing—original draft, Writing—review and editing, Performed biochemical and cellular experiments
    For correspondence
    shunkita@endmet.med.osaka-u.ac.jp
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8937-0053

  2. Shiro Fukuda

    Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan
    Contribution
    Resources, Data curation, Software, Validation, Visualization, Methodology, Writing—review and editing, Cloned the cDNAs of adiponectin receptors
    Competing interests
    No competing interests declared

  3. Norikazu Maeda

    1. Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan
    2. Department of Metabolism and Atherosclerosis, Graduate School of Medicine, Osaka University, Osaka, Japan
    Contribution
    Data curation, Supervision, Funding acquisition, Writing—review and editing
    Competing interests
    No competing interests declared

  4. Iichiro Shimomura

    Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan
    Contribution
    Data curation, Supervision, Funding acquisition, Project administration, Writing—review and editing
    Competing interests
    No competing interests declared

Funding

Japan Science and Technology Agency (#16K09802)

  • Shunbun Kita

Japan Science and Technology Agency (#16K09801)

  • Norikazu Maeda

Japan Science and Technology Agency (#15H04853)

  • Iichiro Shimomura

CREST

  • Iichiro Shimomura

The Uehara Memorial Foundation

  • Iichiro Shimomura

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Acknowledgements

The authors thank the staff of the Center of Medical Research and Education, Graduate School of Medicine Osaka University, for their excellent technical support. This work was supported in part by a Grant-in-Aid for Scientific Research (C) #16K09802 (to SK), a Grant-in-Aid for Scientific Research (C) #16K09801 (to NM), and a Grant-in-Aid for Scientific Research (B) #15H04853 (to IS), the Uehara Memorial Foundation, as well as CREST and JST (to IS). The funders had no role in study design, data collection, and analysis, the decision to publish, or preparation of the manuscript.

Ethics

Animal experimentation: The experimental protocol was approved as No. 28-072-023 by the Ethics Review Committee for Animal Experimentation of Osaka University School of Medicine. This study also conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health.

Copyright

© 2019, Kita et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,637
    views
  • 282
    downloads
  • 35
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Shunbun Kita
  2. Shiro Fukuda
  3. Norikazu Maeda
  4. Iichiro Shimomura
(2019)
Native adiponectin in serum binds to mammalian cells expressing T-cadherin, but not AdipoRs or calreticulin
eLife 8:e48675.
https://doi.org/10.7554/eLife.48675

Share this article

https://doi.org/10.7554/eLife.48675

Categories and tags

Research organisms

Further reading

    1. Cell Biology

    High-throughput expansion microscopy enables scalable super-resolution imaging

    John H Day, Catherine M Della Santina ... Laurie A Boyer
    Tools and Resources

    Expansion microscopy (ExM) enables nanoscale imaging using a standard confocal microscope through the physical, isotropic expansion of fixed immunolabeled specimens. ExM is widely employed to image proteins, nucleic acids, and lipid membranes in single cells; however, current methods limit the number of samples that can be processed simultaneously. We developed High-throughput Expansion Microscopy (HiExM), a robust platform that enables expansion microscopy of cells cultured in a standard 96-well plate. Our method enables ~4.2 x expansion of cells within individual wells, across multiple wells, and between plates. We also demonstrate that HiExM can be combined with high-throughput confocal imaging platforms to greatly improve the ease and scalability of image acquisition. As an example, we analyzed the effects of doxorubicin, a known cardiotoxic agent, on human cardiomyocytes (CMs) as measured by the Hoechst signal across the nucleus. We show a dose-dependent effect on nuclear DNA that is not observed in unexpanded CMs, suggesting that HiExM improves the detection of cellular phenotypes in response to drug treatment. Our method broadens the application of ExM as a tool for scalable super-resolution imaging in biological research applications.

    1. Cell Biology
    2. Developmental Biology

    The exocyst complex controls multiple events in the pathway of regulated exocytosis

    Sofía Suárez Freire, Sebastián Perez-Pandolfo ... Mariana Melani
    Research Article

    Eukaryotic cells depend on exocytosis to direct intracellularly synthesized material toward the extracellular space or the plasma membrane, so exocytosis constitutes a basic function for cellular homeostasis and communication between cells. The secretory pathway includes biogenesis of secretory granules (SGs), their maturation and fusion with the plasma membrane (exocytosis), resulting in release of SG content to the extracellular space. The larval salivary gland of Drosophila melanogaster is an excellent model for studying exocytosis. This gland synthesizes mucins that are packaged in SGs that sprout from the trans-Golgi network and then undergo a maturation process that involves homotypic fusion, condensation, and acidification. Finally, mature SGs are directed to the apical domain of the plasma membrane with which they fuse, releasing their content into the gland lumen. The exocyst is a hetero-octameric complex that participates in tethering of vesicles to the plasma membrane during constitutive exocytosis. By precise temperature-dependent gradual activation of the Gal4-UAS expression system, we have induced different levels of silencing of exocyst complex subunits, and identified three temporarily distinctive steps of the regulated exocytic pathway where the exocyst is critically required: SG biogenesis, SG maturation, and SG exocytosis. Our results shed light on previously unidentified functions of the exocyst along the exocytic pathway. We propose that the exocyst acts as a general tethering factor in various steps of this cellular process.

    1. Cell Biology

    Spatiotemporal recruitment of the ubiquitin-specific protease USP8 directs endosome maturation

    Yue Miao, Yongtao Du ... Mei Ding
    Research Article

    The spatiotemporal transition of small GTPase Rab5 to Rab7 is crucial for early-to-late endosome maturation, yet the precise mechanism governing Rab5-to-Rab7 switching remains elusive. USP8, a ubiquitin-specific protease, plays a prominent role in the endosomal sorting of a wide range of transmembrane receptors and is a promising target in cancer therapy. Here, we identified that USP8 is recruited to Rab5-positive carriers by Rabex5, a guanine nucleotide exchange factor (GEF) for Rab5. The recruitment of USP8 dissociates Rabex5 from early endosomes (EEs) and meanwhile promotes the recruitment of the Rab7 GEF SAND-1/Mon1. In USP8-deficient cells, the level of active Rab5 is increased, while the Rab7 signal is decreased. As a result, enlarged EEs with abundant intraluminal vesicles accumulate and digestive lysosomes are rudimentary. Together, our results reveal an important and unexpected role of a deubiquitinating enzyme in endosome maturation.